These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30344773)

  • 1. Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids.
    Lajkó E; Spring S; Hegedüs R; Biri-Kovács B; Ingebrandt S; Mező G; Kőhidai L
    Beilstein J Org Chem; 2018; 14():2495-2509. PubMed ID: 30344773
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug targeting to decrease cardiotoxicity - determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells.
    Polgár L; Lajkó E; Soós P; Láng O; Manea M; Merkely B; Mező G; Kőhidai L
    Beilstein J Org Chem; 2018; 14():1583-1594. PubMed ID: 30013686
    [No Abstract]   [Full Text] [Related]  

  • 3. Apoptotic Effects of Drug Targeting Conjugates Containing Different GnRH Analogs on Colon Carcinoma Cells.
    Lajkó E; Hegedüs R; Mező G; Kőhidai L
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.
    Kapuvári B; Hegedüs R; Schulcz Á; Manea M; Tóvári J; Gacs A; Vincze B; Mező G
    Invest New Drugs; 2016 Aug; 34(4):416-23. PubMed ID: 27146514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice.
    Ranđelović I; Schuster S; Kapuvári B; Fossati G; Steinkühler C; Mező G; Tóvári J
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.
    Hegedüs R; Manea M; Orbán E; Szabó I; Kiss E; Sipos E; Halmos G; Mező G
    Eur J Med Chem; 2012 Oct; 56():155-65. PubMed ID: 22967796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor.
    Montagnani Marelli M; Manea M; Moretti RM; Marzagalli M; Limonta P
    Int J Oncol; 2015 Jan; 46(1):243-53. PubMed ID: 25351635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification.
    Schuster S; Biri-Kovács B; Szeder B; Buday L; Gardi J; Szabó Z; Halmos G; Mező G
    Pharmaceutics; 2018 Nov; 10(4):. PubMed ID: 30423956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.
    Schuster S; Biri-Kovács B; Szeder B; Farkas V; Buday L; Szabó Z; Halmos G; Mező G
    Beilstein J Org Chem; 2018; 14():756-771. PubMed ID: 29719573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Melanocortin 1 Receptor in Melanoma: Biological Activity of α-MSH-Peptide Conjugates.
    Szabó I; Biri-Kovács B; Vári B; Ranđelović I; Vári-Mező D; Juhász É; Halmos G; Bősze S; Tóvári J; Mező G
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugate.
    Schreier VN; Pethő L; Orbán E; Marquardt A; Petre BA; Mező G; Manea M
    PLoS One; 2014; 9(4):e94041. PubMed ID: 24718594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.
    Szabó I; Bősze S; Orbán E; Sipos É; Halmos G; Kovács M; Mező G
    J Pept Sci; 2015 May; 21(5):426-35. PubMed ID: 25908176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice.
    Manea M; Tóvári J; Tejeda M; Schulcz A; Kapuvári B; Vincze B; Mezo G
    Anticancer Drugs; 2012 Jan; 23(1):90-7. PubMed ID: 21915040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1) cell line.
    Szász Z; Enyedi KN; Takács A; Fekete N; Mező G; Kőhidai L; Lajkó E
    Biomed Pharmacother; 2024 Apr; 173():116293. PubMed ID: 38430628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates.
    Schuster S; Juhász É; Halmos G; Neundorf I; Gennari C; Mező G
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer.
    Dókus LE; Lajkó E; Ranđelović I; Mező D; Schlosser G; Kőhidai L; Tóvári J; Mező G
    Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32580307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted tumor therapy by Rubia tinctorum L.: analytical characterization of hydroxyanthraquinones and investigation of their selective cytotoxic, adhesion and migration modulator effects on melanoma cell lines (A2058 and HT168-M1).
    Lajkó E; Bányai P; Zámbó Z; Kursinszki L; Szőke É; Kőhidai L
    Cancer Cell Int; 2015; 15():119. PubMed ID: 26690297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
    Leurs U; Lajkó E; Mező G; Orbán E; Öhlschläger P; Marquardt A; Kőhidai L; Manea M
    Eur J Med Chem; 2012 Jun; 52():173-83. PubMed ID: 22480495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of novel cyclic NGR peptide-daunomycin conjugates with dual targeting property.
    Tripodi AAP; Tóth S; Enyedi KN; Schlosser G; Szakács G; Mező G
    Beilstein J Org Chem; 2018; 14():911-918. PubMed ID: 29765472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems.
    Murányi J; Varga A; Gyulavári P; Pénzes K; Németh CE; Csala M; Pethő L; Csámpai A; Halmos G; Peták I; Vályi-Nagy I
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.